Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7481 pages
Showing 5001 - 5050Increased Risk of Cardiac Events With High Heart Dose in High-Dose Thoracic Radiotherapy
In a single-center pooled analysis reported in the Journal of Clinical Oncology, Wang et al found that a higher dose of radiation to the heart was associated with an increased risk of cardiac events in patients receiving high-dose radiation therapy for stage III non–small cell lung cancer...
Accelerated Partial-Breast vs Whole-Breast Irradiation After Breast-Conserving Surgery
As reported in The Lancet Oncology by Polgár et al, 5-year late side effects and cosmetic results were similar with accelerated partial-breast irradiation (APBI) with interstitial brachytherapy vs whole-breast irradiation (WBI) after breast-conserving surgery for low-risk invasive and in...
Adding Antiandrogen Therapy to Radiation Therapy in Recurrent Prostate Cancer
As reported in The New England Journal of Medicine by Shipley et al in the NRG Oncology Radiation Therapy Oncology Group (RTOG), the final analysis of the phase III RTOG 9601 trial showed that the addition of antiandrogen therapy with bicalutamide to radiation therapy significantly improves overall ...
Potential Suboptimal Use of Guideline-Endorsed Genomic Testing in Non–Small Cell Lung and Colorectal Cancers
In a study reported in the Journal of Oncology Practice, Gray et al found that many medical oncologists did not use genomic testing endorsed by guidelines in place in 2012 and 2013 in patients with non–small cell lung cancer (NSCLC) and colorectal cancer. The study involved a survey of U.S....
Adjuvant Letrozole vs Anastrozole in Hormone Receptor–Positive Node-Positive Early Breast Cancer
As reported in the Journal of Clinical Oncology by Smith et al, the final results of the phase III FACE trial showed no difference in disease-free or overall survival for adjuvant letrozole vs anastrozole in postmenopausal women with hormone receptor–positive node-positive early breast...
Intermittent Sunitinib Appears Feasible in Previously Untreated Metastatic Renal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Ornstein et al found that an intermittent schedule of sunitinib (Sutent) may be feasible in patients with previously untreated metastatic renal cell carcinoma. Study Details In the study, 37 patients with clear cell metastatic...
Phase III Trial Finds First-Line Ceritinib Improves PFS vs Platinum-Based Chemotherapy in ALK-Rearranged NSCLC
In a phase III trial (ASCEND-4) reported in The Lancet, Soria et al found that ceritinib (Zykadia) improved progression-free survival vs platinum-based chemotherapy in first-line treatment of advanced ALK-rearranged non–small cell lung cancer (NSCLC). Ceritinib is a next-generation selective...
Benefits of Multiparametric Magnetic Resonance Imaging in Clinically Significant Prostate Cancer
In the UK PROMIS study reported in The Lancet, Ahmed et al found that use of multiparametric magnetic resonance imaging (MP-MRI) might reduce the need for transrectal ultrasound (TRUS)-guided prostate biopsy and may improve detection of clinically significant prostate cancer. Study Details In the ...
ASCO Clinical Practice Guideline on Management of Small Renal Masses
As reported in the Journal of Clinical Oncology by Antonio Finelli, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, ASCO has released a clinical practice guideline on management of small renal masses. The guideline was derived from an expert panel literature search for and...
How Does Sublingual Fentanyl Measure Up Against Subcutaneous Morphine in Managing Cancer Pain?
An Italian single-center trial compared treatment with sublingual fentanyl tablets and subcutaneous morphine in managing severe pain episodes in cancer patients receiving opioid treatment. In the Journal of Clinical Oncology, Zecca et al reported that the trial did not show noninferiority of...
Study Finds Addition of Adjuvant Capecitabine to Gemcitabine Improves Survival in Resected Pancreatic Cancer
In the European phase III ESPAC-4 trial reported in The Lancet, Neoptolemos et al found that adding adjuvant capecitabine to gemcitabine significantly improved overall survival in patients with resected pancreatic cancer. Study Details In the open-label trial, 730 patients from 92 hospitals in...
High Financial Burden for CML Patients Enrolled in Medicare Part D Receiving Targeted Oral Therapy
In a study reported in the Journal of Oncology Practice, Shen et al found that more than three-quarters of patients receiving targeted oral therapy for chronic myeloid leukemia (CML) reached the catastrophic phase of the Medicare Part D benefit within the calendar year of starting such treatment....
Trends in Cancer Mortality in the United States and U.S. Counties From 1980 to 2014
In a study reported in JAMA, Mokdad et al found that cancer mortality rates have dropped from 240.2 to 192.0/100,000 population between 1980 and 2014. Mortality rates varied widely among U.S. counties for various cancers. The report covers 29 cancers in 3,144 counties. Summarized here are findings...
Health-Related Quality of Life After Cancer Diagnosis in Adolescents/Young Adults
In a longitudinal study reported in the Journal of Clinical Oncology, Husson et al found that health-related quality of life improved between diagnosis and 2 years after diagnosis in adolescent/young adult (AYA) patients with cancer, but it remained impaired compared with population norms. Study...
Predicting Acute Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy
In a Dutch study reported in the Journal of Clinical Oncology, van den Bogaard et al found that a model including the volume of the left ventricle receiving 5 Gy (LV-V5) might provide improved prediction of acute cardiac events in patients with breast cancer receiving radiotherapy. Prior findings...
Venetoclax Studied in Relapsed or Refractory Non-Hodgkin Lymphoma
The BCL-2 inhibitor venetoclax (Venclexta) was found to be active in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), according to a phase I study reported by Davids et al in the Journal of Clinical Oncology. Further study of this agent, including in combination therapy to augment...
New Molecular-Based Prognostic Model for Glioblastoma in Temozolomide Era
In a study reported in JAMA Oncology, Bell et al derived a molecular-based recursive partitioning analysis model for overall survival in glioblastoma multiforme in the temozolomide era with the aim of refining existing clinically based models. Study Details The study involved analysis of 452...
Low Loss of Residual Lifetime for Patients With DLBCL in Remission Who Were Event-Free 24 Months After Treatment
In a Danish population–based study reported in the Journal of Clinical Oncology, Jakobsen et al found that patients with diffuse large B-cell lymphoma (DLBCL) in first remission and event-free at 24 months after treatment have a low loss of residual lifetime compared with the general...
Potential Surrogate for All-Cause Mortality Risk in Localized Unfavorable-Risk Prostate Cancer
In a study reported in JAMA Oncology, Royce et al found that a prostate-specific antigen (PSA) nadir > 0.5 ng/mL may be a dominant risk factor for all-cause mortality after radiation therapy and androgen-deprivation therapy in men with localized unfavorable-risk prostate cancer. Study Details...
Rucaparib in Previously Treated BRCA Mutation–Associated Ovarian Cancer
On December 19, 2016, rucaparib (Rubraca) was granted accelerated approval for the treatment of patients with deleterious BRCA mutation–associated (germline or somatic) advanced ovarian cancer who have received two or more prior chemotherapy regimens.1,2 The U.S. Food and Drug Administration (FDA) ...
Predicting Outcomes in Older Patients With Cancer
In the French ELCAPA14 study reported in the Journal of Clinical Oncology, Ferrat et al found that four frailty classifications performed well in predicting outcomes in a cohort of patients aged ≥ 70 years with various cancers. Study Details The study involved 763 in- or outpatients with...
Niraparib Maintenance Improves Progression-Free Survival in Platinum-Sensitive Recurrent Ovarian Cancer
In a phase III trial (ENGOT-OV16/NOVA) reported at the 2016 ESMO (European Society for Medical Oncology) Congress and in The New England Journal of Medicine by Mansoor R. Mirza, MD, of the Rigshospitalet–Copenhagen University Hospital, and colleagues, maintenance therapy with the PARP (poly...
Safety of Stopping Imatinib in CML With Undetectable Minimal Residual Disease for at Least 2 Years
As reported in the Journal of Clinical Oncology by Gabriel Etienne, MD, PhD, of the Institut Bergonié, Bordeaux, and colleagues, long-term follow-up in the French Stop Imatinib (STIM1) study indicates that imatinib can be safely stopped in patients with chronic myeloid leukemia (CML) with...
Nivolumab Improves Overall Survival in Recurrent Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
In the phase III CheckMate 141 trial reported in The New England Journal of Medicine, Robert L. Ferris, MD, PhD, of the University of Pittsburgh Medical Center and Cancer Institute, and colleagues found that nivolumab (Opdivo) increased overall survival vs standard therapies in patients with...
ASCO Endorses ASTRO Guideline on Radiation Therapy for Glioblastoma
As reported by Erik P. Sulman, MD, PhD, of MD Anderson Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed the 2016 American Society for Radiation Oncology (ASTRO) evidence-based guideline on radiation therapy for glioblastoma.1 The endorsement was based on review ...
Risk Factors for Estrogen Receptor–Positive and –Negative Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Kerlikowske et al identified risk factors for estrogen receptor–positive and –negative breast cancer using data from the Breast Cancer Surveillance Consortium. The analysis included 1,279,443 women, aged 35 to 74...
Novel Antibody May Reduce Debilitating Symptoms in Patients With Advanced Colorectal Cancer
In a phase III trial reported in The Lancet Oncology, Hickish et al found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite outcome of stabilizing/improving lean body mass and debilitating...
Higher Intake of Grilled/Barbecued and Smoked Meat Linked to Reduced Survival After Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Parada et al found that higher intake of grilled/barbecued and smoked meat may be associated with poorer overall survival in breast cancer survivors. Grilled/barbecued and smoked meat, a source of polycyclic aromatic hydrocarbon...
Similar Survival With Surgery and Chemoradiotherapy in HPV-Negative Oropharyngeal Squamous Cell Cancer
In an observational study reported in JAMA Oncology, Kelly et al found that overall survival was similar with upfront surgery and definitive chemoradiotherapy among patients with newly diagnosed cT1–2 N1–2b human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma....
Venetoclax Plus Rituximab Studied in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a phase Ib study reported in The Lancet Oncology, Seymour et al found that the combination of the BCL2 inhibitor venetoclax (Venclexta) and the anti-CD20 monoclonal antibody rituximab (Rituxan) was highly active in patients with relapsed or refractory chronic lymphocytic leukemia...
Lu-177 Dotatate Improves Progression-Free Survival in Midgut Neuroendocrine Tumors
In a phase III trial (NETTER-1) reported in The New England Journal of Medicine, Strosberg et al found that the addition of the targeted radiotherapeutic agent lutetium Lu-177 dotatate to octreotide long-acting repeatable (LAR) (Sandostatin LAR) significantly improved progression-free...
Pembrolizumab Studied in Locally Advanced or Metastatic Urothelial Cancer
As reported by Plimack et al in The Lancet Oncology, pembrolizumab (Keytruda) has shown activity in patients in the locally advanced or metastatic urothelial carcinoma cohort included in the phase Ib KEYNOTE-012 trial. Study Details In the study, 33 patients with locally advanced or metastatic...
What Influences a Woman’s Decision to Stop Chemopreventive Therapy for Breast Cancer?
In an analysis from the Canadian Cancer Trials Group MAP.3 chemoprevention trial reported in the Journal of Clinical Oncology, Meggetto et al found that worsening of overall menopause-specific quality of life was associated with early discontinuation of study treatment in high-risk postmenopausal...
Most Federal Exchange Plans Under Affordable Care Act Do Not Contain NCI-Designated Cancer Center
In a study reported in the Journal of Clinical Oncology, Kehl et al found that most federal exchange networks under the Affordable Care Act contain a Commission on Cancer–accredited hospital, but less than half contain a National Cancer Institute (NCI)-designated cancer center. Study Details ...
Lower Locoregional Failure but Increased Toxicity With Addition of Cetuximab to Chemoradiotherapy for Anal Carcinoma
In a phase II trial (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group E3205) reported in the Journal of Clinical Oncology, Garg et al found that the addition of cetuximab (Erbitux) to definitive chemoradiotherapy appeared to reduce the...
Is Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer?
Moore et al found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive platinum-resistant ovarian cancer, according to a phase I expansion cohort study reported in the Journal of...
Clonal Hematopoiesis of Indeterminate Potential at Time of ASCT May Be Linked to Adverse Outcomes in Lymphoma
In a study reported in the Journal of Clinical Oncology, Gibson et al found that clonal hematopoiesis of indeterminate potential at the time of autologous stem cell transplantation (ASCT) in patients with lymphoma was associated with an increased risk of poorer outcomes. Study Details In the...
Potential Biomarker of Recurrent Venous Thromboembolism in Cancer Patients Receiving Anticoagulant Therapy
In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Khorana et al found that elevated circulating tissue factor levels were associated with an increased risk of recurrent venous thromboembolism in cancer patients on anticoagulant therapy. CATCH was a randomized ...
Case Report of Regression of Glioblastoma After Chimeric Antigen Receptor T-Cell Therapy
In a brief report in The New England Journal of Medicine, Brown et al described regression of glioblastoma after chimeric antigen receptor (CAR) T-cell therapy. A 50-year-old patient with recurrent multifocal glioblastoma after tumor resection, radiation therapy, and temozolomide was treated with...
Ofatumumab vs Rituximab in Salvage Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The final results of the international phase III ORCHARD study, reported in the Journal of Clinical Oncology by van Imhoff et al, showed no difference in progression-free survival with the addition of ofatumumab (Arzerra) vs rituximab (Rituxan) to cisplatin, cytarabine, and dexamethasone (O-DHAP vs ...
Effect of Sorafenib in Patients With Advanced Hepatocellular Carcinoma May Depend on Hepatitis Status
In a meta-analysis reported in the Journal of Clinical Oncology, Jackson et al found that overall survival with sorafenib (Nexavar) in advanced hepatocellular carcinoma was significantly improved vs comparator treatments among patients who were both hepatitis B virus (HBV)-negative and hepatitis C...
Does Adding Bortezomib to Lenalidomide/Dexamethasone Improve Outcomes in Patients With Newly Diagnosed Myeloma?
In the phase III SWOG S0777 trial reported in The Lancet, Durie et al found that adding bortezomib (Velcade) to lenalidomide (Revlimid)/dexamethasone improved progression-free and overall survival in patients with newly diagnosed myeloma who were not planned for immediate autologous stem cell...
Disappointing Efficacy of Chemotherapy Guided by Ki67 Level After Neoadjuvant AI Therapy for Breast Cancer
In an analysis in the American College of Surgeons Oncology Group (ACOSOG) Z1031 Trial/Alliance reported in the Journal of Clinical Oncology, Ellis et al found that switching to chemotherapy in patients with elevated Ki67 levels after 2 to 4 weeks of neoadjuvant aromatase inhibitor therapy resulted ...
Survival Benefit Reported With Adjuvant Chemotherapy After Nephroureterectomy for Urothelial Carcinoma
In a National Cancer Database analysis reported in the Journal of Clinical Oncology, Seisen et al found that adjuvant chemotherapy after radical nephroureterectomy was associated with an overall survival benefit in patients with locally advanced or regional lymph node–positive upper tract...
How Common Is Cognitive Impairment After Chemotherapy in Breast Cancer Survivors?
In a prospective longitudinal study reported in the Journal of Clinical Oncology, Janelsins et al found that nearly half of women with breast cancer reported a clinically significant decline in cognitive function from before to after chemotherapy, compared with only 10% of age-matched noncancer...
ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care
As reported by Betty R. Ferrell, PhD, of the City of Hope Medical Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on the integration of palliative care into standard oncology care. This update of a 2012 ASCO provisional clinical...
Diagnostic Laparoscopy May Predict Result of Primary Cytoreductive Surgery in Suspected Advanced Ovarian Cancer
In a Dutch trial reported in the Journal of Clinical Oncology, Rutten et al found that initial diagnostic laparoscopy can prevent futile primary cytoreductive surgery in patients with suspected advanced-stage ovarian cancer. Study Details In the trial, 201 women who were qualified for primary...
No Improvement in Event-Free Survival Reported With More Extensive or Serial Resections in Wild-Type GIST
Findings from the National Institutes of Health Pediatric and Wildtype Gastrointestinal Stromal Tumors (GISTs) Clinic, reported in the Journal of Clinical Oncology by Weldon et al, indicate that more extensive or serial resections are not associated with improvement in event-free survival in...
Benefit of Early Integrated Palliative Care in Patients With Newly Diagnosed Incurable Cancer
In a study reported in the Journal of Clinical Oncology, Temel et al found that early integration of palliative care resulted in better quality of life and reduced depression in patients with newly diagnosed incurable lung or noncolorectal gastrointestinal cancer. Outcomes differed by cancer type. ...
Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer
In a study reported in JAMA Oncology, Pearlman et al found that 16% of patients with early-onset colorectal cancer had germline cancer susceptibility mutations, with a wide array of such mutations being identified. The study involved 450 patients diagnosed with colorectal cancer at age < 50...
